The documentations contained in this archive section are provided for historical purposes only. The information contained in each documentation is accurate only as of the date each documentation was originally issued. TME Pharma disavows any obligation to update the information contained in such documentations after the date of their issuance.
2024 - Corporate Presentation
2024, November 22 – SNO 2024: Potentiating the efficacy of immune check-point inhibitors in glioblastoma by inhibition of CXCL12
- download the abstract
- download the poster
2024, September 15 - ESMO 2024: Dual inhibition of postradiogenic angio-vasculogenesis in glioblastoma: Results of the phase 1/2 GLORIA trial
- download the presentation
2023, November 30 - Webinar presenting TME Pharma’s capital increase with preferential subscription rights for fully guaranteed €2.7 million, issued with potential to raise an additional €2.2 million
- view webinar recording
- download the presentation
2023, November 18 – SNO 2023 Annual Meeting Poster Presentation: Interim data on dual inhibition of post-radiogenic angio-vasculogenesis by olaptesed pegol (NOX-A12) and bevacizumab in glioblastoma from the first expansion arm of the Phase 1/2 GLORIA trial.
- download poster
2023, October 21 - ESMO 2023: Spatial remodeling of the immune tumor microenvironment after radiotherapy and CXCL12 inhibition in glioblastoma in the phase 1/2 GLORIA trial
- download the abstract
- download the presentation
2023, June 26 - KOL Webinar: the new biomarker with potential to select brain cancer patients most likely to respond best to NOX-A12
- view webinar recording
- download the presentation
2023, June 03 – ASCO 2023 Annual Meeting Poster Presentation: Potential predictive biomarker for response to radiotherapy and CXCL12-inhibition in glioblastoma in the phase 1/2 GLORIA trial.
- download poster
2022, November 22 - KOL Event Presentation NOX-A12 Phase 1/2 GLORIA trial in glioblastoma
- view webinar recording
- download the presentation
2022, November 18 - TME Pharma presents positive updated results from NOX-A12 Phase 1/2 GLORIA trial in glioblastoma at the 2022 SNO Annual Meeting
- download poster
2022, June 10 - KOL Event Presentation NOX-A12 Phase 1/2 GLORIA trial in glioblastoma
- download the presentation
- download transcript
- view webinar recording
2022, June 05 – NOXXON presents full top-line results from NOX-A12 Phase 1/2 GLORIA trial in glioblastoma at the 2022 ASCO Annual Meeting
- download poster
- view video of ASCO 2022 poster presentation commented by Dr. Frank A. Giordano
2021, November 23 – KOL Webinar with Dr. Frank Giordano on NOX-A12 & Radiotherapy Combination in Brain Cancer incl. Data Presented at the SNO Annual Meeting
- view presentation
- view webinar recording
2021, November 19 – SNO Annual Meeting 2021 Presentation by Dr. Frank Giordano
- view presentation
2020, September - ESMO Congress 2020 Poster Presentation
-download poster
-view presentation
2019, September 30 - Webcast: ESMO Congress 2019 Poster Presentation
-download poster
-download presentation
2019, September 23 - Webinar: What’s next in treatment of brain cancer patients? Testing NOX-A12 with Radiotherapy in a Phase 1/2 Clinical Trial
-download presentation
-download draft script
2024, April 25 - 2023 Annual Report
2023, April 24 - 2022 Annual Report
2022, April 22 - 2021 Annual Report
2021, April 28 - 2020 Annual Report
2020, April 22 - 2019 Annual Report (Corrected version: contains corrected date of signature of the audit opinion, and no other changes.)
2020, April 22 - 2019 Annual Report
2019, April 12 - 2018 Annual Report
2018, April 30 - 2017 Annual Report
2017, June 07 - 2016 Annual Report - statutory
2017, April 30 - 2016 Annual Report - non statutory
2016, December 07 - 2015 NOXXON Pharma N.V. IFRS
2024, Half-Year Financial Report as of 30 June 2024
2023, Half-Year Financial Report as of 30 June 2023
2022, Half-Year Financial Report as of 30 June 2022
2021, Half-Year Financial Report as of 30 June 2021
2020, Half-Year Financial Report as of 30 June 2020
2019, Half-Year Financial Report as of 30 June 2019
2018, Half-Year Financial Report as of 30 June 2018
2017, Half-Year Financial Report as of 30 June 2017
2017, October 30 - Condensed consolidated interim financial statements as of 30 June 2017
2016, October 31 - Condensed consolidated interim financial statements as of 30 June 2016
2017, July 11 - NOXXON Pharma NV Prospectus approved 10 July 2017 (English with summary of prospectus in French)
2016, September 28 - Information Document
Overview and Characteristics of the Convertible Bonds of the financing agreement published on April 23, 2020
as amended on October 14, 2020, January 3, 2022 and May 19, 2022
2024, February 16 - Overview of the Convertible Bonds
2022, May 19 - Press release
2022, January 03 - Press release
2020, October 14 - Characteristics of the Convertible Bonds as amended
2020, October 14 - Press release
2020, April 23 - Characteristics of the Convertible Bonds
2020, April 23 - Press release
Terms of the Warrants of the financing agreement signed on November 15, 2018
2020, April 17 - Overview of the Warrants
2018, November 16 - Terms of the Warrants
2018, November 16 - Press release
Overview and Characteristics of the Convertible Notes listed on Euronext Access Paris in Sept 2018
2018, December 11 - Overview of the Outstanding Notes Listed on Euronext Access Paris - NOXXON7%PT
2018, November 16 - Issuer conversion notices submitted on November 16, 2018
2018, September - Terms and Conditions
2018, September - Euronext Listing Announcement
2018, November 16 - Press release
2018, September 19 - Press release
Overview and Characteristics of the Notes and Warrants of the financing agreement signed on May 01, 2017
2022, June 02 - Updated Summary Table of ODIRNANE & BSA
2017, May 02 - Characteristics of the Warrants
2017, May 02 - Characteristics of the Notes